Johnson & Johnson has begun late stage trials of hepatitis C drug TMC435 as a first line treatment for the …
Pepscan Therapeutics, the biotech firm focusing on protein mimicry technology has signed a deal with Tibotec. Netherlands-based Pepscan will use …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

